Mononuclear phagocytic cells such as monocytes, macrophages and dendritic cells are at the vanguard of our immune system. Harnessing the capabilities of these cells has tremendous potential for fighting disease.
Rather than reprogramming at the level of DNA or RNA, researchers are now using PODS® sustained-release proteins to efficiently reprogram the proteome directly in-vivo.
Whether you are developing new therapies or simply delving into the mechanisms of the immune system, PODS® can help you with your quest.
Affinity-based biosensors use antibodies or aptamers to detect cytokines but suffer from slow dissociation kinetics (half-lives up to ~20 hours). Addressing this kinetic bottleneck enables real-time monitoring of concentration.
Providing building blocks for controlled protein release, the inspired use of PODS is enabling research breakthroughs across biomedical science.
Last week, a Nobel prize was awarded for the discovery of T-Reg cells. When and how many immune cells have been identified and are there likely more lurking in the shadows?
Poor survival of implanted retinal cells has held back therapeutic development. Sustained neurotrophic growth factor release is pushing the field forwards
Sustained release PODS-TGF-B2 enabled powerful modelling of trabecular meshwork,
Rising sea levels, extreme weather, and ecosystem disruption, are well known consequences of climate change, but emerging research also reveals a more intimate threat: climate change may be directly damaging our chromosomes and altering our genetic makeup. This hidden consequence could have profound implications for human health and evolution.
Biological research standards are the invisible agreements that make life science actually scientific. Creating these standards is more complicated (and political) than most people realize.
There are a wide variety of technologies available to concentrate and purify EVs and exosomes. Choosing the right one for your sample and downstream application is critical.
